Physician profile
William Wade Dowell
NPI 1841285764
$5,239.05
in general payments reported to CMS, 2019-2025
30 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $720 · 2021: $734 · 2022: $815 · 2023: $467 · 2024: $743 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.98 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,782.22 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $869.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $402.65 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $324.16 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.22 | 2019-2025 | |
| Pfizer INC. | $254.93 | 2019-2025 | |
| Abbvie INC. | $207.23 | 2021-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $181.24 | 2019-2022 | |
| Astellas Pharma US INC | $176.52 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $112.25 | 2019-2022 | |
| Mylan Specialty L.P. | $108.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.12 | 2019-2022 | |
| Amgen INC. | $53.20 | 2019-2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $44.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.93 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.34 | 2019-2023 | Austedo Xr |
| Ardelyx, INC. | $31.17 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $25.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.94 | 2019 | |
| Insulet Corporation | $19.78 | 2024 | Omnipod |
| Corcept Therapeutics | $18.66 | 2025 | Korlym |
| Lundbeck LLC | $18.17 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
| Shield Therapeutics INC | $17.26 | 2024 | |
| Smith+Nephew, INC. | $15.31 | 2019 | |
| Dexcom, INC. | $14.68 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $14.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.34 | 2019 | |
| Abbott Laboratories | $14.29 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.22 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.